Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Etanercept Versus Monoclonal Antibodies in Axial Spondyloarthritis: Game Over?

GAËLLE VARKAS and DIRK ELEWAUT
The Journal of Rheumatology October 2014, 41 (10) 1899-1902; DOI: https://doi.org/10.3899/jrheum.140866
GAËLLE VARKAS
Department of Rheumatology, University of Ghent, Ghent, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIRK ELEWAUT
Department of Rheumatology, University of Ghent, Ghent, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dirk.elewaut@ugent.be
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

More than 10 years of experience with anti-tumor necrosis factor-α (TNF-α) therapy in ankylosing spondylitis (AS) has brought us new therapeutic players. As respectively infliximab (IFX), etanercept (ETN), adalimumab, golimumab, and certolizumab were introduced, we were confronted with new modes of administration. However, regarding efficacy on axial and peripheral manifestations, all 5 actors seem somewhat equipotent. Also, IFX, ETN, adalimumab, and golimumab have already shown longterm efficacy after 2 to 8 years in established AS1,2,3,4. Nevertheless, treatment with TNF-α blocking agents such as adalimumab and ETN has shown similar high efficacy, with up to 54.5% ASAS40 (Assessment of Spondyloarthritis international Society 40%) response in early disease5,6. In this issue of The Journal, Song, et al report results on the longterm efficacy of ETN in patients with early axial spondyloarthritis (axSpA)7.

Efficacy of TNF-α blocking agents

Generally speaking, 2 types of TNF-α therapy are distinguished: ETN, a soluble TNF-α receptor antagonist, and monoclonal antibodies. All TNF blocking agents display similar short-term efficacy in axSpA4,8,9,10,11,12 (Figure 1). Adalimumab displayed sustained clinical efficacy after 2 years of treatment with an ASAS40 response of 39.4% at Week 24 to an ASAS40 response in 50.6% after 2 years2,10. Also IFX maintained ASAS20 response of 84.8% after 8 years of treatment13. Similar results can be found in ETN and golimumab after 2 years3,4. However, all of these followup studies have been published in AS, generally comprising patients with longer disease duration and more progressive disease.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical efficacy of anti-tumor necrosis factor (TNF)-α agents in ankylosing spondylitis4,8,9,10,11,12. ASAS: Assessment of Spondyloarthritis international Society (guidelines).

Song, et al provide the longterm data of the ESTHER trial with ETN over 3 years. Initially, AS and nonradiographic axSpA (nr-axSpA) with a disease duration of less than 5 years and active inflammation on magnetic resonance imaging (MRI) were treated with ETN or sulfasalazine (SSZ) during a 48-week period. ETN-treated patients responded better regarding MRI inflammation and clinical response than did the SSZ group14. Afterward, all patients were switched to ETN and displayed similar response rates in AS and nr-axSpA, provided that baseline characteristics were comparable6. Notably, the mean disease duration was 2.7 years, depicting early disease. Clinical response was consistently maintained over 1, 2, and even 3 years in both groups with ASAS partial remission obtained in 43.9% of patients. In fact, no differences regarding response of objective markers such as MRI scores and C-reactive protein, or clinical disease activity markers such as Bath AS Disease Activity Index or AS Disease Activity Score, could be detected over time between AS and nr-axSpA. However, we must underline the high dropout rate of almost 50% during this followup period. Therefore these results should be interpreted with caution.

Extraarticular manifestations

Many clinical trials and observational cohorts have shown some inferiority when it comes to the treatment of the extraarticular manifestations (EAM) in SpA. Regarding the treatment of acute anterior uveitis, monoclonal antibodies have proven effective. The effect of ETN, however, is less pronounced. The initial clinical trials in inflammatory bowel disease have shown no efficacy in treatment with ETN15,16.

On the other hand, in SpA-related skin disorders such as psoriasis, the receptor antagonist displays a dose-response relationship, with high dosage of the drug to suppress skin inflammation in a comparable degree to monoclonal antibodies. Psoriasis Area and Severity Index 75 could be achieved in only 26%, possibly underlining the insufficient disease control with ETN in psoriatic arthritis17.

Unfortunately, no longterm ESTHER data regarding EAM are reported in this article. Therefore the longterm effect of ETN on these EAM in early disease remains to be determined.

Safety

Considering various registries across the globe, the overall risk of serious infections associated with anti-TNF is reassuring, especially in young patients and in comparison to other nonbiologic disease-modifying antirheumatic drugs (DMARD). The British registry (BSRBR) presented adjusted hazard ratios declining from 1.8 in the first 6 months to 1.3 in the following months without clear differences across the 3 actors18. The DREAM registry, however, introduced a more generous profile in favor of ETN to IFX and adalimumab, which presented a 2-fold higher risk of serious infections19. Similar findings were reported in the US Safety Assessment of Biologic Therapy registry20. Also, the risk of tuberculosis (TB) and opportunistic infections is remarkably higher in monoclonal antibodies in comparison to ETN21.

Overall, anti-TNF did not show an increased risk of solid malignancies or lymphoma, except for some contradictory reports of a slightly higher risk for non-melanoma skin cancer22. The higher incidence of lymphoma is a known phenomenon in inflammatory diseases, especially rheumatoid arthritis. There are recent data from the BSRBR suggesting a beneficial effect of ETN on the occurrence of mortality and lymphoma in comparison to other DMARD and monoclonal antibodies, but this needs to be confirmed23.

Occurrence of adverse events in 3 year followup of ETN in axSpa consisted mainly of mild upper respiratory tract infections. Only one case of a serious adverse event of sarcoidosis could possibly be linked to ETN therapy. No opportunistic infections, TB, or malignancies were observed. There is ample evidence from registries about the safety profiles of the biologicals regarding infections, malignancies, and overall safety over time, compared to the general population and other DMARD. This setting is more appropriate for the safety evaluation than the “long”-term followup of a small sample size in a clinical trial setting.

Structural damage

The evaluation of radiographic progression is usually performed by the modified Stokes AS spinal score (mSASS). It has been extensively evaluated and validated, despite its known limitations (inclusion of both erosive and osteoproliferative features, and the neglect of the thoracic spine). Initially, anti-TNF failed to deliver the anticipated effect on radiographic progression by reduction of MRI inflammation. However, this was mainly due to the quality of the comparative cohort, the low sensitivity of mSASS, and the inadequate followup period. Haroon, et al could demonstrate a 50% reduction in progression as a result of anti-TNF therapy comparing radiographs more than 1.5 years apart24. Also, several authors have provided data in which patients treated with anti-TNF were followed prospectively for 8 years25,26. Considering Baraliakos, et al25, a difference in progression rate was seen only in the second half of the observation. Strikingly, both groups in both studies exhibited radiographic progression despite “optimal” therapy. The latter findings and the discovery that up to 64% of patients in Ankylosing Spondylitis Disease Activity Score inactive disease and 72% of patients in ASAS partial remission show active inflammation on MRI of the sacroiliac joints or spine under ETN treatment in the ESTHER trial by Song, et al, support the presence of silent disease activity in the absence of overt clinical signs. The effect of this residual disease activity on the longterm structural progression therefore remains to be determined.

TNF-α blocking agents, and most recently ETN, have displayed similar efficacy in short and longterm followup studies in early disease. They do, however, show some discrepancies in the management of extraarticular manifestations and safety profiles.

Regarding the choice of anti-TNF-α, an individual assessment of the patient should be made. Age, comorbidities, concomitant medication, and overall immunosuppression, extraarticular manifestations, risk of infection, living conditions, and even regional aspects (for example, exposure risk to TB) need to be taken into account regarding the choice of anti-TNF-α for the individual patient. The favorable safety profile of ETN may be crucial in some vulnerable patients, whereas the suppression of a recurrent uveitis may be the main clinical problem in others.

As demonstrated by Song, et al, clinical remission may not reflect MRI remission, which highlights the importance of MRI, also in followup. However, additional data regarding the differential evolution of MRI-positive and MRI-negative patients are needed.

REFERENCES

  1. 1.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Fritz C,
    5. Alten R,
    6. Burmester G,
    7. et al.
    Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340–5.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. van der Heijde D,
    2. Schiff MH,
    3. Sieper J,
    4. Kivitz AJ,
    5. Wong RL,
    6. Kupper H,
    7. et al.
    Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922–9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Dijkmans B,
    2. Emery P,
    3. Hakala M,
    4. Leirisalo-Repo M,
    5. Mola EM,
    6. Paolozzi L,
    7. et al.
    Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256–64.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Braun J,
    2. Deodhar A,
    3. Inman RD,
    4. van der Heijde D,
    5. Mack M,
    6. Xu S,
    7. et al.
    Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012;71:661–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Haibel H,
    2. Rudwaleit M,
    3. Listing J,
    4. Heldmann F,
    5. Wong RL,
    6. Kupper H,
    7. et al.
    Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981–91.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Song IH,
    2. Weiss A,
    3. Hermann KG,
    4. Haibel H,
    5. Althoff CE,
    6. Poddubnyy D,
    7. et al.
    Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823–5.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Song IH,
    2. Hermann KG,
    3. Haibel H,
    4. Althoff CE,
    5. Poddubnyy D,
    6. Listing J
    . Spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol 2014;41:2034–40.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Landewé R,
    2. Braun J,
    3. Deodhar A,
    4. Dougados M,
    5. Maksymowych WP,
    6. Mease PJ,
    7. et al.
    Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Davis JC Jr.,
    2. Van Der Heijde D,
    3. Braun J,
    4. Dougados M,
    5. Cush J,
    6. Clegg DO,
    7. et al.
    Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.Arthritis Rheum. 2003;48:3230–6.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. van der Heijde D,
    2. Kivitz A,
    3. Schiff MH,
    4. Sieper J,
    5. Dijkmans BA,
    6. Braun J,
    7. et al.
    Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136–46.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. van der Heijde D,
    2. Dijkmans B,
    3. Geusens P,
    4. Sieper J,
    5. DeWoody K,
    6. Williamson P,
    7. et al.
    Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582–91.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Braun J,
    2. Brandt J,
    3. Listing J,
    4. Zink A,
    5. Alten R,
    6. Golder W,
    7. et al.
    Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187–93.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Baraliakos X,
    2. Listing J,
    3. Fritz C,
    4. Haibel H,
    5. Alten R,
    6. Burmester GR,
    7. et al.
    Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatology 2011;50:1690–9.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Song IH,
    2. Hermann K,
    3. Haibel H,
    4. Althoff CE,
    5. Listing J,
    6. Burmester G,
    7. et al.
    Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590–6.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Sandborn WJ,
    2. Hanauer SB,
    3. Katz S,
    4. Safdi M,
    5. Wolf DG,
    6. Baerg RD,
    7. et al.
    Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–94.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Van Praet L,
    2. Van den Bosch FE,
    3. Jacques P,
    4. Carron P,
    5. Jans L,
    6. Colman R,
    7. et al.
    Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414–7.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Mease PJ
    . Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298–304.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Galloway JB,
    2. Hyrich KL,
    3. Mercer LK,
    4. Dixon WG,
    5. Fu B,
    6. Ustianowski AP,
    7. et al.
    Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124–31.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. van Dartel SA,
    2. Fransen J,
    3. Kievit W,
    4. Flendrie M,
    5. den Broeder AA,
    6. Visser H,
    7. et al.
    Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895–900.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Baddley JW,
    2. Winthrop KL,
    3. Chen L,
    4. Liu L,
    5. Grijalva CG,
    6. Delzell E,
    7. et al.
    Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis 2013 Jul 13 (E-pub ahead of print).
  21. 21.↵
    1. Salmon-Ceron D,
    2. Tubach F,
    3. Lortholary O,
    4. Chosidow O,
    5. Bretagne S,
    6. Nicolas N,
    7. et al.
    Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616–23.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Haynes K,
    2. Beukelman T,
    3. Curtis JR,
    4. Newcomb C,
    5. Herrinton LJ,
    6. Graham DJ,
    7. et al.
    Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48–58.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Mariette X,
    2. Tubach F,
    3. Bagheri H,
    4. Bardet M,
    5. Berthelot JM,
    6. Gaudin P,
    7. et al.
    Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400–8.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Haroon N,
    2. Inman RD,
    3. Learch TJ,
    4. Weisman MH,
    5. Lee M,
    6. Rahbar MH,
    7. et al.
    The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645–54.
    OpenUrlPubMed
  25. 25.↵
    1. Baraliakos X,
    2. Haibel H,
    3. Listing J,
    4. Sieper J,
    5. Braun J
    . Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710–5.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Bennett AN,
    2. McGonagle D,
    3. O’Connor P,
    4. Hensor EM,
    5. Sivera F,
    6. Coates LC,
    7. et al.
    Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 10
1 Oct 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Etanercept Versus Monoclonal Antibodies in Axial Spondyloarthritis: Game Over?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Etanercept Versus Monoclonal Antibodies in Axial Spondyloarthritis: Game Over?
GAËLLE VARKAS, DIRK ELEWAUT
The Journal of Rheumatology Oct 2014, 41 (10) 1899-1902; DOI: 10.3899/jrheum.140866

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Etanercept Versus Monoclonal Antibodies in Axial Spondyloarthritis: Game Over?
GAËLLE VARKAS, DIRK ELEWAUT
The Journal of Rheumatology Oct 2014, 41 (10) 1899-1902; DOI: 10.3899/jrheum.140866
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Efficacy of TNF-α blocking agents
    • Extraarticular manifestations
    • Safety
    • Structural damage
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • New Advances in the Knowledge of Elemental Enthesis Lesions: Doppler, Erosion, and Thickness
  • Keep It in Mind: Assessing the Risk of Dementia in Patients With Rheumatoid Arthritis and Opportunities for Intervention
  • Celebrating The Journal of Rheumatology’s 50th Year of Publication
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire